

Hepatic veno-occlusive disease after liver transplantation: an unusual case report

doi:10.1111/j.1432-2277.2007.00548.x

A 20-year-old female was submitted to liver transplantation because of type I autoimmune cirrhosis. She had triple immunosuppression (cyclosporine, prednisolone, azathioprine) for 10 days, when an episode of acute corticosteroid-resistant cellular rejection developed and was treated with tacrolimus. After 2 years of clinical stability, on tacrolimus and low dose prednisolone, the patient presented with adinamia, anorexia, painful hepatomegaly and ascitis with a serum-ascitis albumin gradient above 1.1 g/dl and high protein content (2.6 g/dl). Blood tests were normal except for normocytic and normochromic anemia (Hb 10.1 g/dl) and high bilirubinemia (1,9 mg/dl). A thoraco-abdominal-pelvic computed tomography showed pleural effusion, ascitis and homogenous hepatosplenomegaly and the coeliac arteriogram and hepatic eco doppler confirmed vascular permeability. Thrombophilia, infection and neoplasia were excluded. Hepatic veno-occlusive disease (VOD) was diagnosed by liver biopsy which revealed the typical signs of this entity: congestion, edema, perivenular hemorrhage at acinar zone 3 and fibrous obliteration of centrilobular veins by connective tissue (Fig. 1).

The above deterioration, not responsive to medical therapy, required a liver re-transplantation, without major complications, except for a mild episode of acute cellular rejection. She remained asymptomatic for 3 years, when a recurrence of VOD, with a similar clinical picture, demanded a third liver transplantation (second re-transplant) which was successful.

Presently, at 30 years old (5 years after the third liver transplant), biliar stenosis was diagnosed and surgically corrected. A liver biopsy performed during surgery showed signs of auto-immune hepatitis and distortion of liver architecture by the presence of porto-portal septa.

The authors are reporting this case because of the rarity of VOD after liver transplantation and also discuss potential predisposing factors and therapeutic options. VOD is a very rare disorder, with a unique etiopathogenesis related to endothelial toxicity leading to fibrotic obliteration of the hepatic centrilobular veins with congestion and hemorrhage of the acinar zone 3 [1–3]. It was initially described in Jamaican consumers of herbal infusions




Figure 1 Fibrous obliteration of centrilobular veins by connective tissue (CAB, 100x).

of *Senecio* and *Crotalaria*, containing pyrrolizidine derived alkaloids [4,5]. Presently, VOD has been found most commonly after bone marrow transplantation with aggressive pretransplant chemotherapy and irradiation regimens [2,6], but additional causes have been described, such as treatment with azathioprine, mainly in renal transplants [7] but also in other diseases.

In liver transplant, VOD is a rare finding [8] and its occurrence has been related either with post-transplant azathioprine treatment or acute cellular rejection [9], both being present in this case. In the largest published series [10], the prevalence of VOD after liver transplantation was 1.9% (19 of 1023 patients). All had been on azathioprine and 89% had previous episodes of acute cellular rejection. Although the pathogenesis of the disease remains unknown, both the use of azathioprine and episodes of acute cellular rejection seem to act as co-factors.

The prognosis depends on the severity of the initial presentation, and the disease can either be reversible or severe with multiorgan failure and death, regardless of treatment. In marrow transplantation more than 50% of the cases have a benign evolution [3,6]. In severe cases, not responsive to medical therapy with drugs like recombinant tectidular plasminogen activator or defibrotide

[11], the transjugular intrahepatic portosystemic shunt has been used with clinical improvement, but with little effect on survival [12]. Liver transplantation is the last resource and may be the only alternative, although with contradictory results [13]. In a previous study [10], 58% of the patients (11/19) were re-transplanted but only three survived. None of these re-transplants was diagnosed with a recurrence of VOD, making our case an extremely rare situation, with only one previous report in the literature [14].

Authorship

A.M. and E.M. wrote the paper. A.C. was responsible for the histopathologic analysis. A.F., J.V., A.M., I.C., A.M. and E.B. contributed to the reviewing of the paper.

Alexandra Martins,¹ Estela Monteiro,¹ António Freire,¹
Ana Carvalho,² Júlio Veloso,¹ Ana Morbey,¹
Isabel Carrilho,¹ Américo Martins¹
and Eduardo Barroso¹
*1 Liver Transplantation Unit,
Hospital Curry Cabral, Lisbon, Portugal*
*2 Pathology Department,
Hospital Curry Cabral,
Lisbon, Portugal*

References

1. Helmy A. Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. *Aliment Pharmacol Ther* 2006; **23**: 11.
2. Shulman Hm, Hinteberger W. Hepatic veno-occlusive disease – liver toxicity syndrome after bone marrow transplantation. *Bone Marrow Transpl* 1992; **10**: 197.
3. Kumar S, DeLeve LD, Kamath PS, Teferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. *Mayo Clin Proc* 2003; **78**: 589.
4. Wilmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to senecio poisoning. *Lancet* 1920; **2**: 848.
5. Bras G, Jelliffe DB, Stuart KL. Venous-occlusive disease of liver with non portal type of cirrhosis, occurring in Jamaica. *Arch Pathol* 1957; **57**: 285.
6. Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. *Transplant Proc* 2005; **37**: 2285.
7. Vallet-Pichard A, Rerolle JP, Fontaine H, et al. Venous-occlusive disease of the liver in renal transplant patients. *Nephrol Dial Transplant* 2003; **18**: 1663.
8. Dhillon AP, Burroughs AK, Hudson M, Shah N, Rolles K, Scheuer PJ. Hepatic venular stenosis after orthotopic liver transplantation. *Hepatology* 1994; **19**: 106.
9. Mion F, Cloix P, Boillot O, et al. Venous-occlusive disease after liver transplantation. Association of acute cellular rejection and toxicity of azathioprine. *Gastroenterol Clin Biol* 1993; **17**: 863.
10. Sebagh M, Debette M, Samuel D, et al. “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. *Hepatology* 1999; **30**: 1144.
11. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. *Blood* 2002; **100**: 4337.
12. Senzolo M, Cholongitas E, Patch D, Burroughs AG. TIPS for veno-occlusive disease: is the contraindication real? *Hepatology* 2005; **42**: 240.
13. Koenecke C, Klein M, Schrem H, et al. Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation. *Int J Hematol* 2006; **83**: 271.
14. Fiel MI, Schiano TD, Klion FM, et al. Recurring fibro-obliterative venopathy in liver allografts. *Am J Surg Pathol* 1999; **23**: 734.